BioWorld Science

July 21, 2022

View Archived Issues

p62 is required to eliminate pathological oligomeric tau species in a mouse model of tauopathy

Dapl1 identified as novel target for cancer immunotherapy

Incyte patents new JAK2 inhibitors

Korea Institute of Science and Technology divulges TGF-beta inhibitors

Wuhan Yuxiang Pharmaceutical Technology identifies SOS1/KRAS interaction inhibitors

Janssen Pharmaceutica synthesizes new CDK7 inhibitors

Hong Kong Baptist University divulges new antiviral compounds

Biallelic variants in RASGRP2 gene tied to bleeding diathesis

Health Canada clears QBKPN to enter clinic to restore innate immunity in elderly

Qu Biologics has received clearance from Health Canada to proceed with a randomized, placebo-controlled trial of QBKPN, a first-in-class innate immune modulator that enhances lung immunity, in the elderly. Read More

SMIM1 gene loss-of-function variant found to increase the risk of stroke

Identification of novel vanin-1 inhibitors

SARS-CoV-2 infection of neurons; no ACE2 required

Today's news in brief

BioWorld

BioWorld briefs for March 12, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...